Sign in
CompletedPhase 1

Zinc Therapy in Critical Illness

Key facts

Who runs it
University of Vermont
Where
Burlington, United StatesSee the site
Trial code
Status
Completed
Phase
Phase 1
People taking part
55 people, planned
Started
Sept 2010
Ended
Dec 2025
Type of study
Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Zinc sulfate
Record updated
1 June 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • Severe sepsis
  • Requiring mechanical ventilation
  • 18 years or older

Who cannot take part

  • Has received zinc supplementation while hospitalized
  • Previous bone marrow or solid organ transplant*
  • Receiving TPN with added zinc
  • Pre-existing gastrointestinal disease*
  • Post-cardiac arrest with significant anoxic brain injury
  • Creatinine clearance <40mL/min*
  • >36 hours since meeting severe sepsis criteria4
  • Expected ICU length of stay <72 hours
  • Taking zinc supplement during past month*
  • Pregnant or lactating*
  • AIDS with CD4<200*

Where in United States

  • University of Vermont College of MedicineBurlington, United States

About the trial

What the trial wants to find out

Sepsis is a clinical syndrome often caused by a bloodstream infection that results in a common set of symptoms termed systemic inflammatory response syndrome (SIRS). Severe sepsis (sepsis with organ failure) is the leading cause of death in critically ill patients in the US. Most patients with severe sepsis need to be treated in the intensive care unit with mechanical ventilation and intravenous antibiotics. Between 30 to 50% of all severe sepsis patients die and quality of life in survivors is substantially reduced. New therapies are needed to improve clinical outcomes in patients with sepsis.

Read full original descriptionShow less

A new area of interest in the treatment of critical illness is pharmaconutrition, in which micronutrients (like zinc) are studied and administered to determine if they affect the inflammatory response or immunologic processes in critical illness. The FDA does not regulate micronutrients and does not require rigorous pharmacokinetic (the study of how a drug or nutrient is metabolized in the body) testing so it is not clear how to dose micronutrients in critically ill patients. It is also not clear if critically ill patients would metabolize these micronutrients differently than healthy people and would need different dosing levels. This is true of zinc, the focus of this research study.

Zinc is essential for normal immune function, oxidative stress response, and wound healing, and its homeostasis is tightly regulated. Zinc deficiency occurs in >10% of Americans and leads to loss of innate and adaptive immunity and increased susceptibility to infections. The symptoms of zinc deficiency are similar to many of the symptoms of SIRS and there is strong biologic rationale to suggest that the zinc deficiency seen in nearly all sepsis patients may contribute to the development of sepsis syndrome and to the "immunoparalysis" common in sepsis patients

This study has three specific aims, 1) to perform a phase I dose-finding study of intravenous zinc in mechanically ventilated patients with severe sepsis; 2) to define the pharmacokinetic of intravenous zinc in mechanically ventilated patients with severe sepsis compared to healthy controls; and 3) to investigate the impact of zinc on inflammation, immunity, and oxidant defense in patients with severe sepsis.

A total of 40 critically ill patients from the FAHC intensive care units and 15 healthy controls will be enrolled in the study. The critically ill patient population will be divided into 4 dosing groups of 10 subjects (7 randomized to zinc and 3 to saline placebo). Group 1 will receive 500mcg/kg IBW/day elemental zinc in divided doses every 8 hours. If the 50th percentile of the normal plasma zinc range (110mcg/dL) has not been achieved in all patients by 7 days and there are no safety concerns, sequential groups of patients will receive increasing doses in 250mcg increments to the ceiling dose. Groups 2 through 4 will receive 750, 1000, and 1250mcg/kgIBW/day elemental zinc, respectively. Each participant will receive the intravenous zinc or placebo for a total of 7 days unless they die or leave the ICU earlier. Pharmacokinetic testing will be obtained from 40 of the critically ill subjects and in 15 healthy controls. Additional blood will be drawn during the infusion protocol to investigate the impact of zinc on inflammation, immunity, and oxidant defense.

The 3 groups in the trial

  • Severe sepsis without zincPlacebo, for comparison

    Mechanically ventilated patients with severe sepsis will be randomized to receive IV zinc or placebo

    Treatment: Zinc sulfate

  • Zinc in severe sepsisTreatment being tested

    Mechanically ventilated patients with severe sepsis will be randomized to receive IV zinc or placebo

    Treatment: Zinc sulfate

  • Healthy Volunteers receiving zincTreatment being tested

    Cohort of healthy volunteers will receive a single dose of 500 mcg/kg IBW IV zinc and pharmacokinetics will be measured for 8 hours. PK in sepsis patients and healthy volunteers will be compared.

    Treatment: Zinc sulfate

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Pharmaconutrients as Therapies for Critical Illness: Zinc in Severe Sepsis
Record updated
1 June 2026